سعر ريفاروسبير 2.5 مجم 2026

Rivaroxaban 2.5 mg film-coated tablets, pack of 30, manufactured by ATCO Pharma for Inspire Pharmaceutical Co. (per Gardenia Pharmacies listing); sold by Egyptian online pharmacies.

• In combination with aspirin, to reduce the risk of major cardiovascular events (CV death, MI, stroke) in coronary artery diseasePopulation: AdultsDailyMed (U.S. National Library of Medicine)
• In combination with aspirin, to reduce the risk of major thrombotic vascular events in peripheral artery disease, including after lower-extremity revascularizationPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Co-administered with ASA (with or without clopidogrel/ticlopidine), prevention of atherothrombotic events after acute coronary syndrome with elevated cardiac biomarkersPopulation: AdultsEuropean Medicines Agency

• The most common adverse reactions are bleeding complications.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Active pathological bleeding.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Severe hypersensitivity reaction to rivaroxaban (e.g. anaphylaxis).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Lesion or condition at significant risk of major bleeding; concomitant treatment with any other anticoagulant except when switching; hepatic disease associated with coagulopathy (incl. Child-Pugh B and C cirrhosis); pregnancy and breast-feeding.International label, same formulation · European Medicines Agency

• Boxed warning: premature discontinuation increases the risk of thrombotic events; consider coverage with another anticoagulant.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning: epidural or spinal haematomas, which may cause long-term or permanent paralysis, can occur with neuraxial anaesthesia or spinal puncture.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Increased risk of bleeding, including serious or fatal bleeding; risk increased with aspirin, P2Y12 inhibitors, other antithrombotics, fibrinolytics, NSAIDs, SSRIs and SNRIs.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Combined P-gp and strong CYP3A inhibitors (e.g. ketoconazole, ritonavir)Increase rivaroxaban exposure and bleeding risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
• Combined P-gp and strong CYP3A inducers (e.g. carbamazepine, phenytoin, rifampin, St John's wort)Decrease rivaroxaban exposure and may increase thromboembolic risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
• Anticoagulants, aspirin, clopidogrel and NSAIDsCoadministration may increase bleeding risk; avoid other anticoagulants unless benefit outweighs risk and evaluate promptly any signs of blood loss.DailyMed (U.S. National Library of Medicine)

• Limited data are insufficient to inform drug-associated developmental risk; use with caution in pregnancy because of potential pregnancy-related haemorrhage and/or emergent delivery.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Contraindicated during pregnancy because of potential reproductive toxicity, intrinsic bleeding risk and placental passage; women of child-bearing potential should avoid becoming pregnant during treatment.International label, same formulation · European Medicines Agency
• Rivaroxaban has been detected in human milk; insufficient data on effects on the breastfed child; weigh benefits of breastfeeding against maternal need.International label, same formulation · DailyMed (U.S. National Library of Medicine)